Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.

TitleTumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.
Publication TypeJournal Article
Year of Publication2022
AuthorsTsui DChun Cheon, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R
JournalClin Lung Cancer
Volume23
Issue2
Paginatione99-e103
Date Published2022 03
ISSN1938-0690
KeywordsAnaplastic Lymphoma Kinase, Carbazoles, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Follow-Up Studies, Humans, Lung Neoplasms, Maximum Tolerated Dose, Piperidines, Protein Kinase Inhibitors, Survival Analysis, Trastuzumab
DOI10.1016/j.cllc.2021.06.012
Alternate JournalClin Lung Cancer
PubMed ID34330640
Grant ListP30 CA046934 / CA / NCI NIH HHS / United States
Related Faculty: 
Liming Bao, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700